Banyan BioInnovations Capital
Banyan BioInnovations Capital last closed a fund in May 2026 — 6 months ago.
1 fund on record — a rhythm needs three. No month is guessed; the filing will say.
This firm closed a fund in the last 18 months, so it has money to put to work now.
- Funds on file
- 1
- Capital raised
- $102M
- Latest close
- May 2026
- Based in
- MA
Vehicles on file
| Vehicle | First close | Amount | Filings |
|---|---|---|---|
| Banyan BioInnovations Capital Fund I LP | May 2026 | $102M | 0002136553 ↗ |
Each row links to that vehicle’s Form D filings on EDGAR — the name, date and amount above should match what is filed there.
Named on filings
Andrew Meyerson, Barbara White, Daniel Brog, Geoffrey Meyerson, Peter Shanley
What Banyan BioInnovations Capital invests in
- Typical fund
- $102M median, early stage, Series A-B scale
What this is. Every figure on this page comes from Form D filings with the U.S. Securities and Exchange Commission — public records, reproduced here as filed. Service providers, where shown, come from the adviser’s Form ADV and are dated.
What it is not. Single-deal SPVs, feeder vehicles and GP or employee commitment funds are listed but excluded from fund counts and capital totals: an SPV is one investment, a feeder holds the same capital as its master, and a “Principals” or “Entrepreneurs” fund closes alongside a main fund rather than being raised in its own right. Capital deployed from a family office, a corporate balance sheet or an evergreen structure never arrives as a fund close, so a firm doing that looks quiet here. Amounts are as of the last amendment and go stale. Dates are the date of first sale — a fund's first close, not its final one. Funds filed as “Indefinite” are excluded from totals rather than counted as zero, so a total is a floor.
“No recent fund” is a statement about filings. It is not a statement about whether a firm is solvent, investing, or still in business.